Posted on Leave a comment

New COVID-19 Clinical Trial Announced To Treat Over 90% of Patients With Underlying Medical Conditions

A new clinical trial is being announced today that could significantly increase the rate of recovery for COVID-19 patients with underlying health conditions and save lives! Circularity Healthcare’s trial will help some of the most at-risk patients suffering from complications due to diabetes, poor circulation, hypertension, cardiovascular disease and high blood pressure. The trial will involve the use of Circularity’s already FDA-approved drug and IDE device D’OXYVA® (deoxyhemoglobin vasodilator) – a non-toxic, non-invasive microcirculation transdermal device.  It is the first biotech solution of its kind to improve overall oxygen-rich blood flow. The device has been shown to significantly heal diabetic wounds, reduce the risks of amputations, prevent sepsis and septic shock,  improve blood pressure and general vital organ function of the pancreas, liver, brain and kidneys, while increasing overall health for some of the most vulnerable patients. 

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

“Anyone who suffers from an underlying condition should know that this proven treatment option is available,” says Circularity Healthcare CEO Norbert Kiss. “Every medical report released so far shows that severe COVID-19 patients need blood oxygenation and blood thinners. The overwhelming majority of patients have diabetes and cardiovascular issues beyond pulmonary complications and they all have sepsis setting in early on. These are the exact main vitals and chronic diseases D’OXYVA improves like no other medication currently available on the market.”

The recommendation for this new treatment is based on the following:

  • After eight years of three dozen human studies with leading experts at some of the most prestigious universities and hospitals in the world (including Penn State and Airlangga University), zero adverse effects were reported. D’OXYVA is currently expanding its Phase 3 trial with Professor David G. Armstrong and his colleagues.
  • The pharmaceutical-grade CO2 utilized by the D’OXYVA device has already been approved by the FDA (it is the same CO2 drug already readily available in every hospital and provided by the same supplier). There is just a 1-2 week IRB approval to launch the trials at any location due to the investigational device exemption (IDE) status of D’OXYVA. Additionally, with the device factory S.-based in Fremont, CA, all the regulated products are also readily-available to launch the trial.
  • The effects of transdermal CO2 have been widely noted in wound care as demonstrated in clinical studies. Healing, closure, prevention against sepsis and septic shock and recovery of an ulcer (non-healing) due to diabetes and cardiovascular complications are much faster and often successful where other modalities have failed.
  • All research projects performed up to date have consistently recorded a significant decrease in systolic blood pressure (from the heart) and diastolic (return to the heart) blood pressure. These results have been consistent throughout all study time periods   up to 240 minutes (the longest time period evaluated after treatment).
  • Systemically, CO2 therapy has shown great success to improve the healthcare of patients with high blood pressure, general vital organ function of patients with high blood pressure, and general vital organ function like that of the pancreas, liver, brain, and kidneys

The clinical trials are now waiting IRB approvals and are about to launch under existing contracts at multiple sites including top U.S. universities such as Harvard, Yale, M.I.T, USC, and UCLA, with more physicians and patients being invited to participate. Since the product can be monitored at home, potential patients do not have to be currently admitted to a hospital in order to take part in the trial. For more information on the trial or to sign up, please visit https://doxyva.com/covid-19/ or call 626.240.0956.

About Circularity Healthcare, LLC
Circularity Healthcare, LLC, located in Los Angeles, CA, is a private biotech and MedTech products and services company that designs, makes, markets, sells, distributes, and licenses its patented and patent-pending technologies, such as its flagship non-invasive deoxyhemoglobin vasodilator product line, D’OXYVA®. One of the main mechanisms underlying D’OXYVA’s science received the Nobel Prize for Medicine in 2019. Circularity enters into exclusive agreements with manufacturers to launch products in large and small clinics and hospitals to help enhance their profits and credit profiles with a wide variety of advanced products and services. In addition, Circularity Healthcare assists in the financing of equipment, working capital, and patient financing at industry-leading terms and speed.

For more information, please visit http://www.circularityhealthcare.com or http://doxyva.com; doctors (Rx only) visit http://wound.doxyva.com and send your general inquiries via the Contact Us page. For specific inquiries, contact Circularity Customer Care at info(at)doxyva(dot)com, info(at)circularityhealthcare(dot)com, or by phone (toll free) at 1-855-5DOXYVA or 1-626-240-0956.

Forward-Looking Information
This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.

Reduce unwanted doctor visits, recommended and ranked top by experts!

Posted on Leave a comment

Join Professional Fitness Icon Eva Marie in a 30-Day D’OXYVA Challenge

Former professional wrestler, actress, and fitness model Eva Marie recently announced a 30-day challenge based on a daily application of D’OXYVA. In a five-minute video on her Instagram page, she and her husband announced that they would both be testing the product to determine the impact on their health and vitality. Marie and the makers of D’OXYVA are also hosting a contest in which her followers can enter to win their own 30-day challenge package.

Share this

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp

Having been an athlete most of her life, Eva Marie has always been a natural fitness enthusiast. After winning the 2012 Powertech Model competition, she joined the WWE in May 2013. Through her time as a wrestler, manager, and actor with the Total Divas, she has always strived for maximum fitness. In recent years, she and her husband have launched social media channels focusing on fashion and fitness and helmed a number of entrepreneurial enterprises, including the Natalie Eva Marie X Ryderwear fashion collection and NEM Fit workout program.

30-Day D’OXYVA Challenge

In part because of the COVID-19 pandemic, Eva Marie and her husband decided to spend their physical distancing time experimenting with various health and wellness programs. Beginning April 17, 2020, the couple decided to use D’OXYVA for the next thirty days and report the results to her fans. To better understand the impact, they will take a few baseline health measurements, such as blood oxygen levels. After the challenge, they will take more measurements to provide anecdotal and statistical comparisons. The video also demonstrates the non-invasive application of the D’OXYVA product.

Why D’OXYVA?

D’OXYVA is a revolutionary new application providing a number of powerful health benefits. At its core, the five-minute, noninvasive application exposes the body to a painless vapor of purified CO2 molecules across the skin. The body responds to this exposure by increasing circulation to the affected areas. Improvements in microcirculation have been proven to lead to a number of positive health outcomes, including greater healing and immune responses.

D’OXYVA has been shown to eliminate nearly all spider and varicose vein markings and speed the healing of open wounds. Improvements in blood flow and nerve stimulation can relieve chronic pain from conditions such as neuropathy or advanced diabetes. As an added benefit, D’OXYVA is a single product that can replace a number of treatments for various conditions. Users can save money and time by consolidating therapies into one application.

Benefits for Healthy People

D’OXYVA is not just for people suffering from chronic conditions. Daily use of D’OXYVA can also provide improvements in circulation and potentially produce benefits related to general fitness, cardiovascular efficiency, and endurance. Eva Marie’s 30-day challenge is intended to allow her to experience and chart these results for the general public, and Marie and the makers of D’OXYVA want to share these benefits with you!

Two lucky people will receive a complete month’s supply of D’OXYVA, including cartridges and the oximeter, to measure blood oxygen levels. Winners will be chosen at random on Monday, April 20, 2020. To enter your name:

 

For More Information:

Don’t wait to join Eva Marie in her 30-day challenge of D’OXYVA! Even if you don’t win, visit https://doxyva.com/shop/ today for great deals on equipment and supplies. You can find sales of up to 35% off for a limited time only!

Reduce unwanted doctor visits, recommended and ranked top by experts!